Sigut
Sigut

Overcoming challenges of lincomycin derivative scale-up

The process of scaling up is always very challenging. While sometimes products can be easily purified through methods like extraction or recrystallization, in certain cases, intermediates present a unique set of obstacles. Such was the scenario in this case where most of the intermediates were rich oily mixtures for which all the attempts of recrystallization failed.

Identifying the issue

SigutLabs undertook the scale-up synthesis of a highly active clindamycin derivative for the Institute of Microbiology of the Czech Academy of Science (Figure 1).

SigutLabs_Figure 1: Total synthesis of clindamycin derivative 1 starting from lincomycin
Figure 1: Total synthesis of clindamycin derivative 1 starting from lincomycin

The given synthetic procedure was only designed for a small scale (100 mg) and contained several hidden issues. An illustrative example was the selective oxidation of -SMe moiety to sulfoxide with m-chloroperoxybenzoic acid (mCPBA). According to the given procedure, only 1 eq. of mCPBA was used even though the oxidation of amine nitrogen in the proline part of the lincomycin was also possible. This expected oxidation might significantly decrease the overall yield of the whole synthesis during scale-up.

Methodology insight

To address this challenge, we devised an alternative approach consisting of mild overoxidation to sulfoxide-N-oxide followed by the selective reduction of N‑oxide with sulfoxide moiety preservation. This action reduced the significant mass losses. Analyzing the intermediates posed another challenge, as the given procedure only utilized TLC for analysis, leaving a lack of information regarding the mixture composition. Moreover, HPLC and a similar method based on light absorption could not be used due to the very low absorption of the intermediates. However, we successfully overcame this challenge by the use of LC/MS as a convenient method for characterizing the crude reaction mixtures (Figure 2).

SigutLabs_Figure 2: LC/MS from Shimadzu
Figure 2: LC/MS from Shimadzu

The last step of the synthesis, the selective chlorination of the secondary hydroxyl group, proved to be even more challenging. The lincomycin derivative molecule contains four secondary hydroxyl moieties which can be subsequently replaced by chlorine atoms. The frequently used chlorination agents (SOCl2, POCl3, PPh3 + NCS, PPh3 + CCl4,…) lead ultimately to overchlorination or undesired elimination of HCl from the molecule. Finally, we identified a mixture of DMF and (COCl)2 to serve our purpose as a very mild chlorination reagent.

Positive outcome

Using these reaction conditions, only traces of overchlorination were observed and ubiquitous elimination was negligible. The final purification process, conducted via reverse column chromatography on multigram scales, yielded the target product with purity exceeding 90 % (Figure 3).

SigutLabs_Figure 3: Automated flash chromatography from Ecom

In summary, through our optimized procedure, we successfully prepared more than 30 g of the desired lincomycin derivatives with excellent purity.

"Our molecule is now in the preclinical phase thanks to scale up done by the SigutLabs team."

Dr. Jiří Janata, Institute of Microbiology of the Czech Academy of Sciences

SigutLabs_Dr Jiri Janata
SigutLabs_1_MBU_cmyk

OUR CASE STUDY

Scale-up to accelerate drug discovery

Our experience helped overcome development hurdles for potential cancer & mental health drugs.

Read more

Empowering neuro research with pro-N6pA

Sigut Labs scaled up pro-N6pA production, simplifying AMPylation research & boosting accessibility.

Read more

ADC development leaps with new linkers

Novel linker design expedited ADC advancement, leading to promising lead compounds faster.

Read more

Lincomycin derivative scale-up

Over 30 g of the desired product with exceptional purity was obtained through our optimized procedure.

Read more

Purifying 350 kg of vitamin K2 oil

Our innovative scale-up technology helped to reduce the client’s purification process from days to hours.

Read more

Our services

What we excel in so you don’t have to

View more
Thumbnail image Custom synthesis

Custom synthesis

Providing for a custom synthesis of previously reported molecules using described synthetic procedures.

Thumbnail image Contract research

Contract research

Developing novel synthetic routes to provide undescribed compounds in organic, bioorganic, and medicinal chemistry.

Thumbnail image Scale-Up

Scale-Up

Helping you go from lab scales to an industrial scale by applying our cutting-edge instrumentation.

Contact
Kryštof

Get in touch

Krystof Sigut, CEO and Founder
arrow

Our Experts

Profile image Krystof Sigut
Krystof Sigut
- CEO and Founder -
International chemical practitioner eager to restore Czech chemistry's global prestige. Contact Krystof for inquiries, NDA signing, or business matters.
Profile image Petr Slavik
Petr Slavik
- Head of Chemistry -
Synthetic chemistry pro with a decade's diverse lab expertise. For offers, research discussions, or detailed insights, reach out to Petr directly.

Partners & distributors

logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner